Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;30(5):269–281. [Article in Spanish] doi: 10.1016/S0212-6567(02)79027-6

Efectividad de la vacuna frente al neumococo en el anciano. Revisión sistemática y metaanálisis

Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis

J Puig-Barberà a,*, A Belenguer Varea b, M Goterris Pinto c, MJ Brines Benlliure c
PMCID: PMC7684164  PMID: 12372207

Abstract

Aim

Estimate pneumococcal vaccine effectiveness in preventing Streptococcus pneumoniae illness in the elderly.

Design

Systematic review and meta-analysis.

Data source

MEDLINE, years 1964 to the 2000; EMBASE, from 1988 to the 2000; Cochrane Library, identified studies and previously published systematic reviews citations peruse, and contacts with field experts.

Study selection

Clinical trials, cohort and case-control studies, published in Spanish, English or French, that estimated pneumococcal disease rates in vaccinated or not vaccinated elderly.

Data extraction

The studies were valued independently by four investigators with predefined criteria of validity, such as results comparing rates of disease caused by serotypes included in the vaccine, random allocation, double blind design, included subjects pertaining to the same study base, and losses of less than 10% in clinical trials and 20% in observational studies.

Results

Eight clinical trials considered the relative risk (RR) of pneumococcal pneumonia, three did not make estimations on pneumonia originated by serotypes included in the vaccine and only one study fulfilled all the inclusion criteria. Vaccinated versus not vaccinated pneumococcal pneumonia RR was 0.86 (95%CI, 0.24 to 2.99). Vaccine effectiveness was 14% (95%CI, −199 to 76%).

Ten studies performed estimations on the effectiveness of the vaccine on invasive disease by vaccine serotypes. Of these, two clinical trials and two observational studies fulfilled the required quality criteria. RR of invasive disease was of 0.68 (95%CI, 0.39–1.18); vaccine effectiveness was 32% (95%CI, –18–61%).

Conclusions

No evidence was found supporting pneumococcal vaccine effectiveness to reduce or avoid S. pneumoniae disease in the elderly.

Key words: Meta-analysis, Pneumococcal infection, Vaccination, Aged

Footnotes

Grupo de Trabajo de Vacunas de la Sociedad Valenciana de Medicina de Familia y Comunitaria (SVMFYC).

Bibliografía

  • 1.Fine M.J., Smith M.A., Carson C.A., Meffe F., Sankey S.S., Weiss-feld L.A. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med. 1994;154:2666–2677. doi: 10.1001/archinte.1994.00420230051007. [DOI] [PubMed] [Google Scholar]
  • 2.CDC Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 1997;46(RR-8):1–24. [PubMed] [Google Scholar]
  • 3.Hutchison B.G., Oxman A.D., Shannon H.S., Lloyd S., Altmayer C.A., Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician. 1999;45:2381–2393. [PMC free article] [PubMed] [Google Scholar]
  • 4.Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract. 2000;1:1. doi: 10.1186/1471-2296-1-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Subdirección General de Prestaciones y Evaluación de Tecnologías Sanitarias, Ministerio de Sanidad y Consumo Informe sobre la vacuna neumocócica. Med Clin (Barc) 1994;102:383–386. [Google Scholar]
  • 6.Gosalbes-Soler V., Márquez-Calderón S., Maiques-Galán A., LatourPérez J., Bernal-Delgado E., Puig-Barberà J. Actividades preventivas en atención primaria: identificación de áreas de concordancia entre guías de práctica clínica basadas en la evidencia. Med Clin (Barc) 2000;114(Supl 2):88–92. [PubMed] [Google Scholar]
  • 7.Austrian R. Surveillance of pneumococcal infection for field trials of polyvalent pneumococcal vaccines. DAB-VDP-12–84, 1–84. 1980 [ref. type: report]. Bethesda (MD), National Institute of Health.
  • 8.Clemens J.D., Shapiro E.D. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis. 1984;6:589–600. doi: 10.1093/clinids/6.5.589. [DOI] [PubMed] [Google Scholar]
  • 9.The Cochrane Library, Issue 1, Updated quarterly. Update Software; Oxford: 2001. [Google Scholar]
  • 10.Jadad A.R., Cook D.J., Jones A., Klassen T.P., Tugwell P., Moher M. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA. 1998;280:278–280. doi: 10.1001/jama.280.3.278. [DOI] [PubMed] [Google Scholar]
  • 11.Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896–1900. doi: 10.1016/s0140-6736(99)04149-5. [DOI] [PubMed] [Google Scholar]
  • 12.Clarke M., Oxman A.D., editors. Cochrane Reviewers’ Handbook 4.0 [updated July 1999]. The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Update Software; Oxford: 2000. [Google Scholar]
  • 13.Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008. [DOI] [PubMed] [Google Scholar]
  • 14.Miettinen O.S. The «case-control» study: valid selection of subjects. J Chronic Dis. 1985;38:543–548. doi: 10.1016/0021-9681(85)90039-6. [DOI] [PubMed] [Google Scholar]
  • 15.Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
  • 16.Sackett D.L., Strauss S.E., Richardson W.S., Rosenberg W., Haynes R.B. How to practice and teach EBM. 2nd ed. Churchill Livingstone; London: 2000. Evidence-based medicine. [Google Scholar]
  • 17.Khan K.S., Daya S., Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996;156:661–666. [PubMed] [Google Scholar]
  • 18.DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  • 19.Egger M., Davey S.G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sharp S. sbe23: meta-analysis regression. Stata Tech Bull. 1998;42:16–24. [Google Scholar]
  • 21.Miettinen O.S. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974;99:325–332. doi: 10.1093/oxfordjournals.aje.a121617. [DOI] [PubMed] [Google Scholar]
  • 22.Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733. doi: 10.1056/NEJM198806303182605. [DOI] [PubMed] [Google Scholar]
  • 23.Altman D.G. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309–1312. doi: 10.1136/bmj.317.7168.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.MacLeod C.M., Hodges R.G., Heidelberg M., Bernhard W.G. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med. 1945;82:445–465. [PMC free article] [PubMed] [Google Scholar]
  • 25.Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide-results of a six year study. Arch Intern Med. 1947;79:518–531. doi: 10.1001/archinte.1947.00220110058004. [DOI] [PubMed] [Google Scholar]
  • 26.Riley I.D., Tarr P.I., Andrews M., Pfeiffer M., Howard R., Challands P. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet. 1977;1:1338–1341. doi: 10.1016/s0140-6736(77)92552-1. [DOI] [PubMed] [Google Scholar]
  • 27.Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA. 1977;238:2613–2616. [PubMed] [Google Scholar]
  • 28.Austrian R. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J Infect Dis. 1977;136(Suppl 1):38–42. doi: 10.1093/infdis/136.supplement.s38. [DOI] [PubMed] [Google Scholar]
  • 29.Bentley D.W., Ha K., Mamot K., Moon D., Moore L., Poletto P. Pneumococcal vaccine in the institutionalized elderly: design of a nonrandomized trial and preliminary results. Rev Infect Dis. 1981;3(Suppl):71–81. doi: 10.1093/clinids/3.supplement_1.s71. [DOI] [PubMed] [Google Scholar]
  • 30.Shapiro E.D., Clemens J.D. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984;101:325–330. doi: 10.7326/0003-4819-101-3-325. [DOI] [PubMed] [Google Scholar]
  • 31.Gaillat J., Zmirou D., Mallaret M.R., Rouhan D., Bru J.P., Stahl J.P. Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution. Rev Epidemiol Sante Publique. 1985;33:437–444. [PubMed] [Google Scholar]
  • 32.Bolan G., Broome C.V., Facklam R.R., Plikaytis B.D., Fraser D.W., Schlech W.F. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med. 1986;104:1–6. doi: 10.7326/0003-4819-104-1-1. [DOI] [PubMed] [Google Scholar]
  • 33.Klastersky J., Mommen P., Cantraine F., Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol. 1986;22:807–813. doi: 10.1016/0277-5379(86)90367-6. [DOI] [PubMed] [Google Scholar]
  • 34.Riley I.D., Lehmann D., Alpers M.P., Marshall T.F., Gratten H., Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet. 1986;2:877–881. doi: 10.1016/s0140-6736(86)90409-5. [DOI] [PubMed] [Google Scholar]
  • 35.Simberkoff M.S., Cross A.P., Al I.M., Baltch A.L., Geiseler P.J., Nadler J. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;315:1318–1327. doi: 10.1056/NEJM198611203152104. [DOI] [PubMed] [Google Scholar]
  • 36.Davis A.L., Aranda C.P., Schiffman G., Christianson L.C. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest. 1987;92:204–212. doi: 10.1378/chest.92.2.204. [DOI] [PubMed] [Google Scholar]
  • 37.Forrester H.L., Jahnigen D.W., LaForce F.M. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med. 1987;83:425–430. doi: 10.1016/0002-9343(87)90751-0. [DOI] [PubMed] [Google Scholar]
  • 38.Leech J.A., Gervais A., Ruben F.L. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ. 1987;136:361–365. [PMC free article] [PubMed] [Google Scholar]
  • 39.Sims R.V., Steinmann W.C., McConville J.H., King L.R., Zwick W.C., Schwartz J.S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108:653–657. doi: 10.7326/0003-4819-108-5-653. [DOI] [PubMed] [Google Scholar]
  • 40.Gable C.B., Holzer S.S., Engelhart L., Friedman R.B., Smeltz F., Schroeder D. Pneumococcal vaccine. Efficacy and associated cost savings. JAMA. 1990;264:2910–2915. doi: 10.1001/jama.264.22.2910. [DOI] [PubMed] [Google Scholar]
  • 41.Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  • 42.Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993;270:1826–1831. [PubMed] [Google Scholar]
  • 43.Farr B.M., Johnston B.L., Cobb D.K., Fisch M.J., Germanson T.P., Adal K.A. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995;155:2336–2340. [PubMed] [Google Scholar]
  • 44.Koivula I., Sten M., Leinonen M., Makela P.H. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997;103:281–290. doi: 10.1016/s0002-9343(97)00149-6. [DOI] [PubMed] [Google Scholar]
  • 45.Ortqvist A., Hedlund J., Burman L.A., Elbel E., Hofer M., Leinonen M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vacci-nation Study Group. Lancet. 1998;351:399–403. doi: 10.1016/s0140-6736(97)07358-3. [DOI] [PubMed] [Google Scholar]
  • 46.Honkanen P.O., Keistinen T., Miettinen L., Herva E., Sankilampi U., Laara E. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493–2500. doi: 10.1016/s0264-410x(99)00069-9. [DOI] [PubMed] [Google Scholar]
  • 47.Nichol K.L., Baken L., Wuorenna J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 2000;159:2437–2442. doi: 10.1001/archinte.159.20.2437. [DOI] [PubMed] [Google Scholar]
  • 48.Benson K., Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–1886. doi: 10.1056/NEJM200006223422506. [DOI] [PubMed] [Google Scholar]
  • 49.Concato J., Shah N., Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892. doi: 10.1056/NEJM200006223422507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735. doi: 10.1001/jama.285.13.1729. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES